Cardiotoxicity Market: Overview
Cardiotoxicity is a major concern in chemotherapies, and hence the mechanisms underlying chemotherapy-induced cardiotoxicity attract substantial interest in healthcare systems. The drive for improving the effectiveness of chemotherapies, such as in breast cancer in recent years, has bolstered clinical trials and other similar research in the cardiotoxicity market.
Chemoterapics drugs have oftentimes been associated with cardiotoxicity, leading to myocardial dysfunction and even irreversible heart failure. Frequently, these risks have been confirmed by the parameters of echocardiography used in clinical settings. Over the years, a growing body of research and advances in imagistic methods have underscore such research. Evolution in cardio-oncology field has been charting the growth trajectories in the cardiotoxicity market.
The study offers a critical assessment of the clinical research directions that will shape notable avenues in the cardiotoxicity market. The research also takes a closer look at factors and the dynamics that influence the current and emerging competitive landscape, along with the share and revenue size of various key segments during the forecast period of 2020 – 2030.
Do you want to assess potential implications of COVID-19 pandemic on your business and boost your preparedness? Grab an exclusive sample for this report!
Cardiotoxicity Market: Key Trends
The strides in the cardiotoxicity market are influenced by the adoption of targeted anticancer agents. Resultantly, interested stakeholders are evaluating the cardiovascular complication (CVC) potential associated with the currently accepted chemotherapies. CVS, among other risk factors, have been bothering cancer patients who are on prolonged chemotherapies. Numerous regulatory bodies highlight the key risk factors of chemotherapy-induced cardiotoxicity, such as coronary artery disease, arrhythmias, and thromboembolic diseases.
Growing numbers of cancer survivors in various parts of the world have spurred research in cardio-oncology, which will help in reducing the population with concomitant cardiovascular diseases. Thus, the expansion of cardiotoxicity market is being considered as an important one for oncologists around the world. They are increasingly focused on weighing the trade-off between life-threatening CVCs and life-saving chemotherapies.
However, sub-clinical nature of cardiac alteration poses considerable challenge for oncologist. This points to an unmet need in the cardiotoxicity market.
Key cardiotoxicity types are left ventricle dysfunction, rhythm disturbances, and ischaemia. Major end users where the cardiotoxicity market is seeing revenues are hospitals, clinics, and ambulatory surgical centers.
Are you a start-up willing to make it big in business? Grab an exclusive PDF Brochure for this report
Cardiotoxicity Market: Competitive Analysis and Key Developments
Researchers are striving to come out with better understanding of pathophysiology. The objective is to improve the diagnosis of cardiac dysfunction in patients with chemotherapy-induced cardiotoxicity. In recent years, the focus has shifted to the use of retrospective studies in understanding the mortality and morbidity associated with chemotherapy-induced cardiotoxicity. The efforts of industry players have opened new avenues in the cardiotoxicity market. A promising trend is growing research data on targeted therapy-related CVCs. An example is trastuzumab-induced cardiac toxicity.
On the other hand, pharmaceutical players are expanding their research area to include cardioprotective drugs to be used alongside some chemotherapies. This has unlocked a steady revenue streams for aspiring players in the cardiotoxicity market.
Some of the key market participants are Cook Medical Incorporated, Becton Dickson Company, Cardinal Health Inc, C. R. Bard, and LivaNova PLC. Some other key players are St. Jude Medical, Terumo Cardiovascular Systems Corporation, Biotronik, Medtronic, Boston Scientific Corporation, and Johnson & Johnson.
Cardiotoxicity Market: Regional Assessment
Regionally, Europe and North America are lucrative markets. The rapid evolution of these regional markets have been driven by the regulatory push toward rigorous cardiac monitoring plans in clinical trials. Such trials help in early detection of toxicity. Numerous technologies are being developed in these regions to meet the demand for chemotherapy-induced cardiac damage.
Industry stakeholders in the cardiotoxicity market are keen on unveiling new biomarkers for targeted therapy-related CVCs, thereby opening new revenue streams in the developed world, including in Asia Pacific. Rapid evolution of cardio-oncology has also bolstered the revenue potential of Asia Pacific in the global cardiotoxicity market.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.